Database Query Results : , , MBD2

MBD2, Methyl-CpG binding domain protein 2: Click to Expand ⟱
Source:
Type:
Mbd2 drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition.

In many cancers, high MBD2 expression is associated with poor prognosis, indicating a more aggressive tumor phenotype and potential resistance to therapy. This is often due to its role in silencing tumor suppressor genes through DNA methylation.
When MBD2 activity is high:
-Tumor suppressor genes remain silenced
-Differentiation programs stay off
-Stem-like and proliferative states persist
-Epigenetic reprogramming becomes resistant to reversal

Loss or inhibition of MBD2 can reactivate silenced genes even without changing DNA methylation.


Scientific Papers found: Click to Expand⟱

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 0

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: MBD2, Methyl-CpG binding domain protein 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:521  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page